Share on StockTwits
 

Anacor Pharmaceuticals (NASDAQ:ANAC) SVP Kirk R. Maples unloaded 3,000 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $20.27, for a total transaction of $60,810.00. Following the completion of the sale, the senior vice president now directly owns 9,620 shares in the company, valued at approximately $194,997. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Separately, analysts at Canaccord Genuity raised their price target on shares of Anacor Pharmaceuticals from $17.00 to $24.00 in a research note to investors on Tuesday, October 29th. They now have a “buy” rating on the stock.

Anacor Pharmaceuticals (NASDAQ:ANAC) traded up 9.44% during mid-day trading on Wednesday, hitting $22.72. The stock had a trading volume of 1,069,243 shares. Anacor Pharmaceuticals has a 52 week low of $3.00 and a 52 week high of $20.81. The stock’s 50-day moving average is $17.09 and its 200-day moving average is $12.08. The company’s market cap is $925.7 million.

Anacor Pharmaceuticals (NASDAQ:ANAC) last announced its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.39) by $0.02. The company had revenue of $3.60 million for the quarter, compared to the consensus estimate of $2.57 million. During the same quarter last year, the company posted ($0.46) earnings per share. Anacor Pharmaceuticals’s revenue was up 45.7% compared to the same quarter last year. Analysts expect that Anacor Pharmaceuticals will post $2.02 EPS for the current fiscal year.

Anacor Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.